https://oncdata.com/article/f0622f5e-cc97-43e2-b8dd-c4887b0835e1Oncology Data Advisoren2026-11-15T02:49:20.637ZInfectious Complications and Antimicrobial Resistance Across Cancer Immunotherapies https://oncdata.com/article/619cdb6f-a5e0-41b1-a1a8-d5581658419fOncology Data Advisoren2026-11-15T02:49:20.537ZMeasurable Residual Disease in Multiple Myeloma https://oncdata.com/article/dd210ffc-8cde-4f90-a552-cbd93fa70655Oncology Data Advisoren2026-11-14T22:49:23.319ZEarly vs Routine Oral Nutritional Supplementation for Nasopharyngeal Carcinoma https://oncdata.com/article/7a9c4bb1-709c-40d0-b4e8-f6be8421ca13Oncology Data Advisoren2026-11-14T22:49:23.230ZReal-World Effectiveness and Safety of Tarlatamab in Pretreated Small Cell Lung Cancer https://oncdata.com/article/ef861f57-f466-40ca-99a5-df16b4430496Oncology Data Advisoren2026-11-14T02:49:50.278ZMolecular and Immunologic Profiling of HER2-Low Advanced Gastric Cancer https://oncdata.com/article/26bb6190-e429-4f97-b970-5e64b28bea83Oncology Data Advisoren2026-11-14T02:49:50.192ZPSA Screening Benefits and Harms: Systematic Review for the American Cancer Society Guideline Update https://oncdata.com/new-combination-approach-to-kmt2a-rearranged-infant-leukemiaOncology Data Advisoren2026-11-13T14:03:33.382ZA New Combination Approach to KMT2A-Rearranged Infant Leukemia https://oncdata.com/article/cd8bb946-2881-41fd-9ffe-5a96f549baaeOncology Data Advisoren2026-11-13T12:49:54.689ZPerioperative Camrelizumab (Investigational) With Chemotherapy Improves EFS in Resectable HNSCC https://oncdata.com/article/0590a61d-266b-4197-97c6-63ec39fc067aOncology Data Advisoren2026-11-13T12:49:54.486ZLong-Term Second Cancer Risks in Female Hodgkin Lymphoma Survivors Across Treatment Eras